EVO

Eaton Vance Ohio Municipal Income Trust

EVO

Market cap $4.39B

Overview Fund Activity

Delisted

EVO was delisted on the 18th of January, 2019.

Back to rankings

Financial journalist opinion

Evotec SE (EVO) Q2 2025 Earnings Call Transcript

Evotec SE (NASDAQ:EVO ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Christian Wojczewski - CEO & Management Board Member Cord Dohrmann - Chief Scientific Officer & Member of Management Board Paul Hitchin - CFO & Member of Management Board Volker Braun - Executive VP and Head of Global Investor Relations & ESG Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Charles Robert Weston - RBC Capital Markets, Research Division Christian Ehmann - Warburg Research GmbH Douglas Dylan Tsao - H.C. Wainwright & Co, LLC, Research Division Fynn Scherzler - Deutsche Bank AG, Research Division Joseph Hedden - Rx Securities Limited, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Operator Ladies and gentlemen, welcome to the Evotec SE Half Year Report 2025 Conference Call.

Evotec SE (EVO) Q2 2025 Earnings Call Transcript

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect strategic focus Group revenues of € 371.2 m (-5%); D&PD (-11%) continues to see soft demand;Just - Evotec Biologics ("JEB"; +16%) exceeding expectations driven by broadened customer base Key progress in collaborations with Bristol Myers Squibb ("BMS") on targeted protein degradation and neuroscience Evolution of strategic partnership with Sandoz announced on 30 July HAMBURG, DE / ACCESS Newswire / August 13, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced financial results for H1 2025, demonstrating clear progress in the implementation of its new strategy for sustainable and profitable growth; highlighting Just - Evotec Biologics' strong growth as it transitions to an asset-lighter model. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "We are firmly on track with the execution of our strategy: Evotec is making meaningful strides toward sustainable and profitable growth.

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

Evotec SE to announce first half-year results 2025 on 13 August 2025

HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE to announce first half-year results 2025 on 13 August 2025

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration, future development revenues, milestones and product royalties.

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology The deal terms include the purchase price of the site for around US$ 300 m in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties Planned transaction marks major milestone in Evotec's strategy to create asset-lighter business model leveraging high-margin offerings, with Just - Evotec Biologics remaining core business for Evotec Transaction is expected to immediately improve Evotec's short-, mid-, and long-term revenue mix, profit margins, and capital efficiency HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU, which owns the J.POD biologics manufacturing facility in Toulouse, France, and to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license. The site has been customised and dedicated entirely to Sandoz since July 2024, and the transaction is a natural progression in an already successful partnership.

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec: Recovery Seems To Be Beginning

Evotec remains a speculative 'Buy' with a €20/share price target, offering high long-term potential but requiring patience for upside realization. The company is refocusing on core strengths, expanding Evotec Biologics, leveraging AI, and executing cost-saving measures to improve profitability. Despite high leverage and recent revenue declines, strong partnerships, a robust pipeline, and operational improvements support my continued investment thesis.

Evotec: Recovery Seems To Be Beginning

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.

Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license revenues expected to have a stronger impactthan anticipated Significant cost optimization in excess of initial targets from Priority Reset Shared R&D base businesscontinues to navigate in a challenging market environment H1 2025 Group revenues below expectations; adj. EBITDA broadly in line with expectations Revenue guidance adjusted; R&D and adjusted EBITDA guidance unchanged, reflecting improved revenue mix and cost discipline Evotec confirms itsOutlook 2028 HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has updated its revenue guidance for the fiscal year 2025.

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease ("CKD") transition and pediatric AKI. This partnership will enable Evotec to understand human disease progression on a molecular level and to perform targeted drug discovery in the field of AKI.

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

See News Rankings

Charts implemented using Lightweight Charts™